JAK2 and Venous thrombosis: Indeed, the JAK2-gain-of-function mutation has been shown to promote the risk of venous and coronary thrombosis and pulmonary embolus, due to its enhanced formation of neutrophil extracellular traps, components of innate immunity [43] Importantly, however, the JAK2V617F mutation was also found to be associated with thrombosis in patients without the presence of myeloproliferative neoplasms or other hematologic disorders [43].